Latest News

13

Oct2023

Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer

0  
by John Copertino / / Publications
Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
October 13, 2023

12

Oct2023

Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines

0  
by webmaster / / Publications
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
October 12, 2023

05

Oct2023

Phase 2 Study of nab-Sirolimus in Patients with Well-differentiated and Advanced or Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract, Lung, or Pancreas

0  
by webmaster / / Publications
October 5, 2023

05

Oct2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

0  
by webmaster / / Publications
October 5, 2023

30

Sep2023

0  
by webmaster / / Uncategorized
test
September 30, 2023

02

Jun2023

Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)

0  
by John Copertino / / Publications
Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)
June 2, 2023

19

Apr2023

Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations

0  
by webmaster / / Publications
April 19, 2023

18

Apr2023

Synergistic Antitumor Activity of nab-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts

0  
by webmaster / / Publications
April 18, 2023

17

Apr2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

0  
by webmaster / / Publications
April 17, 2023

27

Mar2023

Mohammad Hirmand, MD

0  
by webmaster / / BOD
Dr. Hirmand has served on the Company’s board of directors since March of 2023 and is a co-founder of Avenzo Therapeutics, a privately held oncology company, and serves as its executive vice president and chief medical officer.  Previously, Dr. Hirmand served as executive vice president and chief medical officer of Turning ... Read More
March 27, 2023